Regulatory-ready CDMO Avioq operates an FDA-licensed manufacturing facility and ISO 13485:2016 certification with a proven track record of navigating regulatory pathways, presenting a strong turnkey option for clients seeking fast, compliant product development and manufacture.

In-house Assay Portfolio The company develops and manufactures its own FDA and CE-marked diagnostic assays (including HTLV-I/II and HIV profiles), enabling potential partners to leverage existing validated platforms, faster time-to-market, and reduced regulatory risk.

End-to-end CDMO Capabilities span exploratory research through feasibility studies to manufacturing, offering a full spectrum service that can accelerate partner projects from concept to market with integrated quality systems.

Global Compliance Footprint Products already have CE marking and Health Canada approvals, indicating readiness for multi-region commercialization and potential for expansion into additional regulated markets alongside current FDA alignment.

Proven Diagnostics Expertise With a 25-year track record in designing and developing immunoassay-based diagnostics, Avioq can position itself as a trusted innovator for new infectious disease diagnostics and companion assay development for contract programming.